-
Feb 20, 2024 | 
onclive.com | Jeffrey Zonder
Jeffrey Zonder, MD, leader, Multiple Myeloma and Amyloidosis Multidisciplinary Team, Barbara Ann Karmanos Cancer Institute; vice chair, M1 IRB Committee, Wayne State University, discusses the outcomes of the phase 3 PERSEUS trial (NCT03710603) in patients with relapsed/refractory multiple myeloma. Findings from the randomized PERSEUS trial at a median follow-up of 47.5 months were presented at the 2023 ASH Annual Meeting.
-
Feb 12, 2024 | 
onclive.com | Jeffrey Zonder
February 12, 2024Jeffrey Zonder, MD, discusses notable unmet needs that remain to be addressed in the treatment of patients with relapsed/refractory multiple myeloma.
-
Jan 22, 2024 | 
onclive.com | Jeffrey Zonder |Shaji K Kumar
Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.
-
Jan 22, 2024 | 
onclive.com | Jeffrey Zonder |Shaji K Kumar
ctDNA Is Predictive of DFS, Offers Prognostic Tool in CRCFrontline Nivolumab/Ipilimumab Provides Superior PFS Benefit Over Chemo in MSI-H/dMMR mCRCDr Li on the Use of ADG126 With Pembrolizumab in MSS CRCReal-World Data Identify Factors Associated With Long-Term Response to Regorafenib in mCRC
-
Dec 19, 2023 | 
newsbreak.com | Jeffrey Zonder
By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
-
Dec 19, 2023 | 
onclive.com | Jeffrey Zonder |Shaji K Kumar
Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding DisordersZanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)Acquired BTK and PLCG2 Mutations May Not Drive Progression After Zanubrutinib/Ibrutinib Treatment in Relapsed CLLResponses With Pirtobrutinib Remain High Despite Acquired Resistance in Relapsed CLL/SLL
-
Nov 17, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Jack Khouri, MD: So, Greg, we seem like a big fan of this. Craig Cole, MD: I didn’t want to tell you. But the patients that I had on [the trial] are what make me a fan. The patients I had when we had to discontinue in November had to stop therapy and remain in very good, or even CRs [complete responses] for months and months. I think the longest one is a patient I still have from November when I discontinued, and she’s still in a CR.
-
Nov 10, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Judy Schreiber, PhD, RN: We’ll go on to the next presentation, which will be Dr [Craig] Cole presenting on the DREAMM-3 study [NCT04162210]. Craig Cole, MD: Thanks, and I was just an investigator on the DREAMM-6 study [NCT03544281]. I want to thank everyone for inviting me, and Dr Weisel for sharing her slides with me. So belantamab mafodotin or Blenrep is a humanized anti-BCMA conjugated antibody.
-
Nov 10, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Craig Cole, MD: Faiz, where do you think you’d use a regimen like this? I think this was a French study done a few years ago. How do you think this fits into the landscape these days? Faiz Anwer, MD, FACP: I think this fits in with the more frail or [older] patients. A significant number of patients are not close to a major academic center. There’s a significant number of patients who don’t want to travel so frequently.
-
Nov 3, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
